10-Q: Ionis Pharmaceuticals Q3 2025: Revenue Soars on New Launches

Ionis Pharmaceuticals reports significantly increased revenue and narrowed net loss in Q3 2025, driven by new product launches and strategic collaborations.

Summary

• Total revenue for the nine months ended September 30, 2025, increased to $740.4 million, up from $478.6 million in the same period of 2024.
• Commercial revenue grew by 42% year-over-year to $294.5 million, primarily due to the launch of TRYNGOLZA and increased WAINUA royalties.
• Product sales from TRYNGOLZA, launched in the U.S. in December 2024, generated $57.4 million in the first nine months of 2025.
• Research and development revenue significantly increased to $445.9 million, up from $271.2 million, largely due to a $280 million upfront payment from the Ono collaboration for sapablursen.
• Net loss for the nine months ended September 30, 2025, narrowed to $152.0 million, a substantial improvement from a $349.5 million net loss in the prior year period.
• Operating expenses increased to $907.6 million from $842.8 million, driven by higher selling, general and administrative (SG&A) expenses related to product launches, partially offset by a slight decrease in R&D expenses.
• Cash and cash equivalents stood at $338.3 million as of September 30, 2025, with total cash, cash equivalents, and short-term investments at approximately $2.24 billion.
• Net cash used in operating activities significantly improved to $130.9 million for the nine months ended September 30, 2025, compared to $384.8 million in the prior year period.
• A $29.4 million unrealized gain was recorded in Q3 2025 related to an investment in a privately held company, partially offset by an $18.2 million impairment in Q2 2025.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant revenue growth driven by new product launches and strategic collaborations, a substantial reduction in net loss, and positive late-stage clinical trial results. While operating expenses increased and net loss persists, the overall trajectory indicates strong operational execution and pipeline advancement.

Positives

• Total revenue for the nine months ended September 30, 2025, increased by 54.7% to $740.4 million compared to $478.6 million in the same period of 2024.
• Commercial revenue increased by 42% year-over-year, driven by new product sales and higher royalties.
• Successful U.S. launches of TRYNGOLZA (December 2024) and DAWNZERA (August 2025) are establishing new independent revenue streams.
• TRYNGOLZA received EU approval in September 2025, expanding its market reach.
• WAINUA royalties significantly increased to $33.1 million for the nine months ended September 30, 2025, from $10.3 million in the prior year.
• A $280 million upfront payment was received from Ono Pharmaceutical Co., Ltd. for the sapablursen collaboration, contributing significantly to R&D revenue.
• Positive topline Phase 3 results were announced for olezarsen in severe hypertriglyceridemia (sHTG) and zilganersen in Alexander disease (AxD) in September 2025.
• Initiated the Phase 3 REVEAL study for ION582 in Angelman syndrome in June 2025.
• Net loss significantly narrowed to $152.0 million for the nine months ended September 30, 2025, from $349.5 million in the prior year, indicating improved operational efficiency and revenue generation.
• Net cash used in operating activities improved substantially to $130.9 million from $384.8 million year-over-year.

Negatives

• The company continues to incur a net loss, totaling $152.0 million for the nine months ended September 30, 2025.
• Selling, general and administrative (SG&A) expenses increased significantly by 47% to $263.7 million for the nine months ended September 30, 2025, due to commercialization activities for new product launches.
• The 0% Convertible Senior Notes, with an outstanding principal balance of $632.5 million, were reclassified from non-current to current liabilities as they are due in April 2026, impacting current liquidity metrics.
• An $18.2 million impairment of an investment in a privately held company was recorded in the second quarter of 2025.

Risks

• Ability to generate substantial revenue from the sale of medicines, including the success of new independent launches.
• Availability of adequate coverage and payment rates for medicines from third-party payers, potentially impacted by U.S. healthcare reform measures like the Inflation Reduction Act (IRA) and 'most-favored nation' pricing policies.
• Intense competition from major pharmaceutical and specialized biopharmaceutical firms, including products like onasemnogene abeparvovec and risdiplam against SPINRAZA, and plozasiran against TRYNGOLZA and WAYLIVRA.
• Regulatory limitations following approval, such as restrictions on product labels, off-label promotion prohibitions, and requirements for post-approval clinical studies.
• Dependence on collaborations with partners like Biogen and AstraZeneca for the development and commercialization of key medicines (SPINRAZA, QALSODY, WAINUA), with partners potentially prioritizing other programs or terminating agreements.
• Challenges in expanding manufacturing capabilities and reliance on third-party manufacturers, which could lead to delays, increased costs, or non-compliance with cGMP regulations.
• Failure to obtain regulatory approval for pipeline medicines or additional approvals for commercial medicines, or delays in these processes.
• High inherent risks in drug discovery and development, with potential for clinical study failures or delays, as seen with past programs like QALSODY's VALOR study and tominersen's GENERATION HD1 study.
• Dependence on third parties (e.g., CROs, clinical investigators) to conduct clinical studies, with risks of delays due to labor shortages or geopolitical conflicts impacting study sites (e.g., Israel).
• Potential loss of Orphan Drug exclusivity, which could increase competition and reduce market share.
• Need for additional funding in the future, which may lead to dilution of existing stockholders if raised through equity offerings, or unfavorable terms if raised through debt.
• Inability to protect patent rights and other proprietary rights, as evidenced by the ongoing patent infringement lawsuit with Arrowhead Pharmaceuticals.
• Exposure to potential product liability claims inherent in testing, manufacturing, marketing, and sale of therapeutic products.
• Loss of key personnel or inability to attract and retain highly skilled employees.
• Adverse effects on business from health epidemics, climate change, extreme weather events, war, civil or political unrest, terrorism, or disruptions of the U.S. government.
• Data protection risks, including cybersecurity threats and non-compliance with data privacy regulations, potentially leading to financial penalties or reputational harm.
• Volatility in the company's stock price due to various factors, including operating results, financing transactions, clinical study outcomes, and broader market conditions.
• Limitations on the ability to use net operating loss carryovers and other tax attributes due to ownership changes (Sections 382/383) or state-level restrictions (e.g., California SB 167).
• Potential for increased tax liabilities due to changes in tax laws, regulations, or interpretations, including those related to the OECD's BEPS project.

Future Outlook

Ionis Pharmaceuticals anticipates continued increases in operating expenses, excluding non-cash compensation, for the remainder of 2025 as commercialization activities for new launches advance. Development expenses are expected to stabilize as late-stage studies conclude and resources are reallocated to earlier-stage programs. The company plans to independently launch olezarsen for severe hypertriglyceridemia and zilganersen for Alexander disease by the end of 2026, assuming regulatory approval. Phase 3 data for pelacarsen is on track for the first half of 2026, and enrollment for the ION582 REVEAL study is expected to be completed in 2026. The company believes its current cash, cash equivalents, and short-term investments will be sufficient to fund planned operations and obligations.

Management Comments

• "For three decades, we have invented medicines that bring better futures to people with serious diseases."
• "With our commercial launch of TRYNGOLZA... we began a new chapter as a fully integrated commercial-stage biotechnology company."
• "Our key recent achievements, combined with our independent and partnered product launches anticipated by the end of 2027, position us well to help patients with serious diseases and to deliver increasing product and royalty revenue."
• "We expect our operating expenses, excluding non-cash compensation expense related to equity awards, to continue to increase during the remainder of 2025 as we advance our commercialization activities."
• "We expect our development expenses will continue to stabilize as several late-stage studies end and we reallocate resources toward earlier stage programs."
• "We believe our cash, cash equivalents and short-term investments, as well as plans for cash in the future, will be sufficient to fund our planned operations and these obligations."

Industry Context

Ionis Pharmaceuticals is solidifying its position as a fully integrated commercial-stage biotechnology company, a significant shift from its historical reliance on partnerships. The successful launches of TRYNGOLZA and DAWNZERA, alongside the co-commercialization of WAINUA, demonstrate a growing internal commercial capability. The positive late-stage clinical trial results for olezarsen and zilganersen further strengthen its pipeline, particularly in rare and cardiometabolic diseases, which are areas of high unmet medical need and significant market potential. The increasing R&D revenue from collaborations, such as the Ono deal, highlights the continued value of its RNA-targeted technology platform in a competitive biopharmaceutical landscape. However, the industry faces ongoing pressures from healthcare cost control initiatives, including those from the Inflation Reduction Act, which could impact future drug pricing and reimbursement.

Comparison to Industry Standards

• The company's entry into independent commercialization with TRYNGOLZA and DAWNZERA positions it alongside more established biopharmaceutical companies that manage their own sales and marketing infrastructure, rather than solely relying on partners like Biogen for SPINRAZA or AstraZeneca for WAINUA outside the U.S.
• The significant increase in WAINUA royalties (from $10.3M to $33.1M year-over-year) suggests a strong market uptake for this ATTRv-PN treatment, potentially outperforming some new drug launches in the rare disease space.
• The $280 million upfront payment from Ono for sapablursen reflects a robust valuation for its RNA-targeted technology and pipeline assets, comparable to significant licensing deals seen in the industry for promising late-stage candidates.
• The ongoing patent dispute with Arrowhead Pharmaceuticals over plozasiran (an ApoCIII inhibitor) highlights the competitive landscape in lipid-lowering therapies, where companies like Akcea (Ionis's subsidiary) and Arrowhead are vying for market share with similar mechanisms of action.
• The company's net loss, while improving, indicates it is still in a growth phase requiring substantial investment, which is common for biotech companies with multiple products in development and recent commercial launches, but contrasts with profitable, fully mature pharmaceutical companies.

Corporate Governance

Legal Proceedings

• On September 10, 2025, Arrowhead Pharmaceuticals, Inc. filed a lawsuit in the District of Delaware seeking a declaratory judgment that Ionis's patent US9,593,333 is invalid or not infringed by use of Arrowhead's ApoCIII inhibitor plozasiran.
• On September 11, 2025, Ionis filed suit in the Central District of California asserting infringement of patent US9,593,333 by Arrowhead's announced intention to commercialize plozasiran in November 2025.
• On October 8, 2025, Ionis filed a motion to dismiss, or in the alternative, transfer Arrowhead's Delaware suit in favor of the case brought in the Central District of California. Both lawsuits remain pending.

Stakeholder Impact

• **Shareholders:** Positive impact from significant revenue growth, narrowed net loss, and strong pipeline progress, potentially leading to increased shareholder value. However, potential future dilution from capital raises and ongoing litigation risks could be a concern.
• **Patients:** Positive impact from the launch of new medicines like TRYNGOLZA and DAWNZERA, and the advancement of pipeline candidates like olezarsen and zilganersen, offering new treatment options for serious diseases.
• **Employees:** Continued investment in commercialization and R&D activities suggests stable to growing employment opportunities, particularly in sales, marketing, and scientific roles.
• **Partners (e.g., AstraZeneca, Biogen, Ono):** Strengthened collaborations and new agreements (like Ono) indicate continued mutual benefit and shared development efforts. Successful launches and pipeline advancements enhance the value of these partnerships.
• **Creditors:** The reclassification of $630.9 million in 0% Convertible Senior Notes to current liabilities highlights a significant short-term obligation, which could be a point of attention, although the company's cash position appears sufficient.

Next Steps

• Independently launch olezarsen for severe hypertriglyceridemia (sHTG) by the end of 2026, assuming regulatory approval.
• Independently launch zilganersen for Alexander disease (AxD) by the end of 2026, assuming regulatory approval.
• Complete enrollment for the Phase 3 REVEAL study of ION582 in Angelman syndrome in 2026.
• Anticipate Phase 3 data for pelacarsen in the first half of 2026.
• Ono Pharmaceutical Co., Ltd. to initiate a pivotal clinical trial for sapablursen, which would trigger a $20 million milestone payment.
• AstraZeneca to advance a medicine under the cardiovascular, renal and metabolic diseases collaboration, which would trigger a $20 million payment.
• Continue regulatory review process for DAWNZERA in the EU.
• Assess the impact and timing of adopting new accounting standards ASU 2025-05 and ASU 2025-07.
• Early adopt ASU 2025-06 on January 1, 2026, on a prospective basis.

Key Dates

Recommendation

Ionis Pharmaceuticals demonstrates strong operational momentum with significant revenue growth driven by successful new product launches (TRYNGOLZA, DAWNZERA) and increased royalties from existing commercial products (WAINUA). The substantial narrowing of net loss and improved cash flow from operations indicate a positive financial trajectory. Positive late-stage clinical data for key pipeline assets like olezarsen and zilganersen further de-risk future growth. While increased SG&A expenses are expected with commercialization efforts and the 0% convertible notes are now a current liability, the overall financial health, robust pipeline, and strategic collaborations position the company for continued growth and market penetration. The ongoing patent litigation with Arrowhead is a factor to monitor, but the overall outlook is favorable for long-term investors.

Keywords

Ionis Pharmaceuticals, Biotechnology, RNA-targeted therapeutics, SEC 10-Q, Q3 2025 Earnings, TRYNGOLZA, DAWNZERA, WAINUA, SPINRAZA, Olezarsen, Zilganersen, Clinical Trials, Drug Development, Commercialization, Biopharma, Rare Diseases, Familial Chylomicronemia Syndrome, Hereditary Angioedema, Transthyretin Amyloidosis, Spinal Muscular Atrophy, Alexander Disease, Hypertriglyceridemia, Angelman Syndrome, Collaborative Agreements, Financial Results